Twin Tree Management LP raised its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 708.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 85,210 shares of the company's stock after buying an additional 74,666 shares during the period. Twin Tree Management LP's holdings in AstraZeneca were worth $5,583,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC lifted its holdings in AstraZeneca by 1.1% in the third quarter. FMR LLC now owns 23,117,447 shares of the company's stock valued at $1,801,080,000 after buying an additional 258,477 shares during the period. Franklin Resources Inc. grew its stake in AstraZeneca by 8.7% during the third quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company's stock worth $1,492,649,000 after purchasing an additional 1,522,715 shares during the period. Jennison Associates LLC increased its holdings in AstraZeneca by 3.1% in the fourth quarter. Jennison Associates LLC now owns 15,430,963 shares of the company's stock worth $1,011,037,000 after purchasing an additional 466,416 shares in the last quarter. Fisher Asset Management LLC lifted its stake in AstraZeneca by 4.6% in the fourth quarter. Fisher Asset Management LLC now owns 10,959,852 shares of the company's stock valued at $718,090,000 after buying an additional 479,692 shares during the period. Finally, Manning & Napier Advisors LLC boosted its holdings in shares of AstraZeneca by 17.7% during the 4th quarter. Manning & Napier Advisors LLC now owns 3,745,531 shares of the company's stock worth $245,407,000 after buying an additional 564,297 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.
Wall Street Analysts Forecast Growth
AZN has been the subject of several research reports. UBS Group upgraded AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th. Morgan Stanley assumed coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They set an "overweight" rating for the company. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $89.75.
View Our Latest Stock Analysis on AZN
AstraZeneca Stock Performance
Shares of NASDAQ AZN traded down $1.59 during mid-day trading on Friday, reaching $74.93. 5,172,805 shares of the company's stock were exchanged, compared to its average volume of 4,940,222. The firm has a market capitalization of $232.37 billion, a price-to-earnings ratio of 33.16, a price-to-earnings-growth ratio of 1.42 and a beta of 0.41. The firm has a 50-day moving average price of $72.67 and a two-hundred day moving average price of $72.19. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74. AstraZeneca PLC has a 52 week low of $62.75 and a 52 week high of $87.68.
AstraZeneca (NASDAQ:AZN - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing analysts' consensus estimates of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. Analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.
AstraZeneca Increases Dividend
The company also recently disclosed a semi-annual dividend, which will be paid on Monday, March 24th. Investors of record on Friday, February 21st will be issued a $1.03 dividend. The ex-dividend date of this dividend is Friday, February 21st. This represents a yield of 2%. This is a positive change from AstraZeneca's previous semi-annual dividend of $0.49. AstraZeneca's dividend payout ratio (DPR) is 91.15%.
AstraZeneca Company Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
